The effects of renal replacement therapy on plasma, asymmetric dimethylarginine, nitric oxide and C-reactive protein levels

Clinical and Investigative Medicine

Volumn 31, Issue 1, 2008, Pages

  Uzun, Hafize ^a   Konukoglu, Dildar ^a,c   Besler, Mine ^b   Erdenen, Fusun ^b   Sezgin, Can ^a   Muderrisoglu, Cuneyt ^b  

^a ISTANBUL UNIVERSITY   (Turkey)

^b Istanbul Education and Research Hospital   (Turkey)

^c NONE   (Turkey)

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN; N(G),N(G) DIMETHYLARGININE; NITRIC OXIDE; UREA;

ADULT; ARTICLE; BLOOD LEVEL; CHRONIC KIDNEY DISEASE; CLINICAL ARTICLE; CONTROLLED STUDY; ENDOTHELIAL DYSFUNCTION; FEMALE; HEMODIALYSIS; HUMAN; MALE; OUTPATIENT CARE; PERITONEAL DIALYSIS; PRIORITY JOURNAL; RENAL REPLACEMENT THERAPY; UREA BLOOD LEVEL;

ADULT; ARGININE; ATHEROSCLEROSIS; C-REACTIVE PROTEIN; ENDOTHELIUM, VASCULAR; FEMALE; HUMANS; INFLAMMATION; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; NITRIC OXIDE; PERITONEAL DIALYSIS, CONTINUOUS AMBULATORY; RISK FACTORS; TIME FACTORS;

EID: 39449136798     PISSN: 0147958X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (35)

1. Hadi HA, Carr CS, Al Suwaidi J. Endothelial dysfunction: cardiovascular risk factors, therapy, and outcome. Vasc Health Risk Manag 2005;1:183-98.
2. Inoue N. Vascular C-reactive protein in the pathogenesis of coronary artery disease: role of vascular inflammation and oxidative stress. Cardiovasc Hematol Disord Drug Targets. 2006;6:227-31.
3. Yang Z, Kaye DM. Endothelial dysfunction and impaired L-arginine transport in hypertension and genetically predisposed normotensive subjects Trends Cardiovasc Med 2006;16:118-24.
4. Wever R, Boer P, Hijmering M et al. Nitric oxide production is reduced in patients with chronic renal failure. Arterioscler Thromb Vasc Biol 1999;19:1168-72.
5. Schmidt RJ, Yokota S, Tracy TS, Sorkin MI, Baylis C. Nitric oxide production is low in end-stage renal disease patients on peritoneal dialysis. Am J Physiol 1999;276 :F794-797.
6. Vallance P, Leone A, Calver A, Collier J, Moncada S. Accumulation of an endogenous inhibitor of nitric oxide synthesis in chronic renal failure. Lancet 1992;339:572-5.
7. Cooke JP. ADMA: its role in vascular disease. Vasc Med 2005;10:Suppl 1:S11-17.
8. Szuba A, Podgorski M. Asymmetric dimethylarginine (ADMA) a novel cardiovascular risk factor - evidence from epidemiological and prospective clinical trials. Pharmacol Rep 2006;58:16-20.
9. de Ferranti SD, Rifai N. C-reactive protein: a nontraditional serum marker of cardiovascular risk. Cardiovasc Pathol 2007;16:14-21.
10. Zoccali C, Benedetto FA, Mallamaci F et al. Inflammation is associated with carotid atherosclerosis in dialysis patients. J Hypertens 2000;18:1207-13.
11. Daugirdas JT, Depner TA, Gotch FA et al . Comparison of methods to predict equilibrated Kt/V in the HEMO Pilot Study. Kidney Int 1997;52:1395-405.
12. Shinzato T, Nakai S, Fujita Y et al. Determination of Kt/V and protein catabolic rate using pre- and postdialysis blood urea nitrogen concentrations. Nephron 1994;67:280-90.
13. Desjardins F, Balligand JL. Nitric oxide-dependent endothelial function and cardiovascular disease. Acta Clin Belg 2006;61:326-34.
14. Roccatello D, Mengozzi G, Alfieri V et al. Early increase in blood nitric oxide, detected by electron paramagnetic resonance as nitrosylhaemoglobin, in haemodialysis. Nephrol Dial Transplant 1997;12:292-7.
15. Matsumoto A, Hirata Y, Kakoki M et al. Increased excretion of nitric oxide in exhaled air of patients with chronic renal failure. Clin Sci (Colch) 1999;96:67-74.
16. Baylis C. Nitric oxide deficiency in chronic renal disease. Eur J Clin Pharmacol 2006;62:Suppl 1:123-130.
17. Passauer J, Pistrosch F, Bussemaker E, Lassig G, Herbrig K, Gross P. Reduced agonist-induced endothelium-dependent vasodilation in uremia is attributable to an impairment of vascular nitric oxide.J Am Soc Nephrol 2005;16:959-65.
18. Wever R, Boer P, Hijmering M et al. Nitric oxide production is reduced in patients with chronic renal failure. Arterioscler Thromb Vasc Biol 1999;19:1168-72.
19. Vallance P, Leone A, Calver A Collier J, Moncada S. Accumulation of an endogenous inhibitor of nitric oxide synthesis in chronic renal failure. Lancet 1992;339:572-5.
20. Wanner C, Zimmermann J, Schwedler S, Metzger T: Inflammation and cardiovascular risk in dialysis patients. Kidney Int 2002;61:99-102.
21. Stenvinkel P, Heimburger O, Paultre F et al. Strong association between malnutrition, inflammation, and atherosclerosis in chronic renal failure. Kidney Int 1999;55:1899-911
22. Panichi V, Migliori M, De Pietro S et al. C-reactive protein in patients with chronic renal diseases. Ren Fail 2001;23:551-62.
23. Burkart JM, Depner TA: End-stage renal disease and dialysis. NephSAP 2005;4:293-350.
24. Ronco C, Bowry S, Tetta .Dialysis patients and cardiovascular problems: Can technology help solve the complex equation? Blood Purif 2006;24:39-45
25. Hon WM, Lee JC, Lee KH. Effect of hemodialysis on plasma nitric oxide levels. Artif Organs 2000;24:387-90.
26. Fayed HM, Kame MA, Sultan MM, Mowafy MN, Helmy SM ,El-Zoghby MH. Nitric oxide generation by peripheral blood cells in chronic renal failure. Br J Biomed Sci 2002;59:24-9.
27. Schmidt RJ, Yokota S, Tracy TS, Sorkin MI, Baylis C. Nitric oxide production is low in end-stage renal disease patients on peritoneal dialysis. Am J Physiol 1999:F794-7.
28. Zoccali C, Enia G, Tripepi G, Panuccio V, Mallamaci F. Clinical epidemiology of major nontraditional risk factors in peritoneal dialysis patients. Perit Dial Int 2005;3:S84-87.
29. Rysz J, Luciak M, Kedziora J, Blaszczyk J, Sibinska E. Nitric oxide release in the peripheral blood during hemodialysis. Kidney Int 1997;51:294-300.
30. Arici M, Walls J. End-stage renal disease, atherosclerosis, and cardiovascular mortality: is C-reactive protein the missing link? Kidney Int 2001;59:407-14.
31. Panichi V, Migliori M, De Pietro S et al. C-reactive protein in patients with chronic renal diseases. Ren Fail 2001;23:551-2.
32. Oflaz H, Pusuroglu H, Genchallac H et al. Endothelial function is more impaired in hemodialysis patients than renal transplant recipients. Clin Transplant 2003;17:528-33.
33. Passauer J, Büssemaker E, Range U, Plug M, Peter Gross P. Evidence In Vivo Showing Increase of Baseline Nitric Oxide Generation and Impairment of Endothelium-Dependent Vasodilation in Normotensive Patients on Chronic Hemodialysis. J Am Soc Nephrol 2001;1:1726-34.
34. Wanner C, Zimmermann J, Schwedler S, Metzger T. Inflammation and cardiovascular risk in dialysis patients. Kidney Int 2002;61:S99-102.
35. Termorshuizen F, Dekker FW, van Manen JG, Korevaar JC, Boeschoten EW, Krediet RT: Relative contribution of residual renal function and different measures of adequacy to survival in hemodialysis patients: An analysis of the Netherlands Cooperative Study of the Adequacy of Dialysis (NECOSAD)-2. J Am Soc Nephrol 2004;15:1061-70.